Publications by authors named "Clint Maart"
Article Synopsis
- The study investigates how monocyte subsets change after elective percutaneous coronary intervention (PCI) and their connection to inflammation in heart disease.
- Intermediate monocytes (CD14++CD16+) were found to decrease shortly after PCI, recover in two weeks, and significantly increase at two months, particularly in patients with drug-eluting stents (DES).
- Additionally, specific gene expressions and humoral biomarkers showed notable changes, with some remaining elevated for weeks post-procedure, indicating that the type of PCI might influence the inflammatory response.
Background: Primary percutaneous coronary intervention (pPCI) with drug-eluting stents (DES) has emerged as the standard of care, but stent-related events have persisted. Drug-coated balloon (DCB)-only angioplasty is an emerging technology, although it is not fully evaluated compared with DES in the context of pPCI.
Objectives: The aim of this study was to investigate the safety of DCB-only angioplasty compared with second-generation DES in pPCI.
Article Synopsis
- The study compares the effectiveness of drug-coated balloons (DCBs) versus second-generation drug-eluting stents (DESs) in treating new cases of unprotected left main stem (LMS) disease.
- The research involved 148 patients and found no significant differences in all-cause mortality (19.5% for DCB vs. 15.9% for DES) or cardiac mortality between the two treatment options.
- The results indicate that DCBs are a safe alternative for treating LMS disease, with outcomes similar to DES after a median follow-up of 33 months.
Objective: We aimed to investigate the safety of drug-coated balloon (DCB)-only angioplasty compared to drug-eluting stent (DES), as part of routine clinical practice.
Background: The recent BASKETSMALL2 trial demonstrated the safety and efficacy of DCB angioplasty for de novo small vessel disease. Registry data have also demonstrated that DCB angioplasty is safe; however, most of these studies are limited due to long recruitment time and a small number of patients with DCB compared to DES.
Article Synopsis
- The study aimed to assess the long-term survival rates of patients treated with paclitaxel drug-coated balloons (DCB) during percutaneous coronary intervention (PCI).
- Recent safety concerns about paclitaxel devices, linked to increased late mortality for peripheral artery disease, have prompted this research focused on coronary interventions, where data is limited.
- The results indicated no significant late mortality risk from DCB angioplasty compared to non-paclitaxel drug-eluting stents (DES), suggesting that DCB is a safe treatment option for new coronary artery disease cases.
Objective: To report our initial experience with drug coated balloon (DCB) only angioplasty and propose a protocol to achieve this safely.
Background: There are no articles published in the literature currently regarding the safety of same day discharge in patients treated with DCB-only angioplasty.
Methods: Retrospective review of all our patients treated with DCB-only angioplasty from September 2017 to April 2018 with identification of potential complications relating to same day discharge.